Quantcast

Latest Systemic lupus erythematosus Stories

2014-03-27 12:27:48

New England Patriots defensive back Tavon Wilson serves as Walk Ambassador WASHINGTON, March 27, 2014 /PRNewswire-USNewswire/ -- Multi-talented entertainer and television personality Nick Cannon will serve as the Grand Marshal at the Walk to End Lupus Now(TM) event in Washington, D.C. on Saturday, April 19. Cannon will cut the opening ceremony ribbon and lead the more 4,000 walkers down Pennsylvania Avenue towards the Capitol, shedding light on the cruel mystery that is lupus....

2014-03-25 08:29:48

HERZLIYA, Israel, March 25, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced the appointment of Daniel J. Wallace, MD and Murray Urowitz, MD, two experts in rheumatology, as consultants for the planned Phase II trial for the Company's hCDR1...

2014-03-20 12:32:58

LFA-REAL(TM) System is first of its kind tool to bring patients deeply into the development process WASHINGTON, March 20, 2014 /PRNewswire-USNewswire/ -- The Lupus Foundation of America announced today that it is funding and leading the development of a first-of-its-kind tool to monitor lupus disease activity called the LFA-REAL((TM))(Rapid Evaluation of Activity in Lupus) System. LFA-REAL will address major challenges in lupus treatment and disease management, and has the potential...

2014-03-18 23:02:43

Discounted research study “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData is now available at MarketPublishers.com. According to the report, new product launches are set to fuel SLE and LN treatment markets expansion through to 2022. London, UK (PRWEB) March 18, 2014 The systemic Lupus Erythematosus (SLE) treatment market in the 7 major nations (the US, Germany, France, the UK, Italy, Japan,...

2014-03-17 12:27:32

--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, March 17, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of clinical studies with its lead compound RSLV-132. Resolve administered the first doses to humans of RSLV-132 its first-in-class targeted nuclease therapy designed to decrease the burden of circulating RNA-containing immune complexes in SLE patients. Ongoing studies are designed to evaluate the safety, tolerability,...

2014-03-12 20:24:20

HAYWARD, Calif., March 12, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and operational update for the fourth quarter and year ended December 31, 2013. Fourth Quarter and Fiscal Year 2013 Financial Results: Net loss for the fourth quarter and year ended December 31, 2013 was $9.2 million and $30.9 million, respectively. Operating expense for the year ended December 31, 2013 was $28.2 million as compared to $55.9 million for...

2014-03-11 23:33:04

Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with systemic lupus erythematosus (SLE). Birmingham, Alabama (PRWEB) March 11, 2014 *To see if you qualify for this Lupus Clinical Trial in Birmingham, visit Achieve Clinical Research on the web (http://www.achieveclinical.com/) or contact us directly at (205) 380-6434. There is no cost to participate, no...

2014-02-26 23:33:54

The new “Autoimmune Disease Treatment” writing on the website Vkool.com covers natural ways to treat autoimmune diseases effectively. Seattle, Wa (PRWEB) February 26, 2014 The new “Autoimmune Disease Treatment” article on the site Vkool.com delivers to readers easy tips to cure autoimmune disorders. The report is divided into two main sections. In the first section of the report, people will get to know common causes of autoimmune diseases, such as family history, hormonal status,...

2014-02-04 16:29:30

Lupus Research Organizations Welcome Big-Science Push to Drive New Therapies for Lupus Patients NEW YORK, Feb. 4, 2014 /PRNewswire/ -- The Alliance for Lupus Research (ALR) and the Lupus Research Institute (LRI) are proud to join the National Institutes of Health (NIH) in the Accelerating Medicines Partnership (AMP) launched today to speed new paths to treatment for lupus and autoimmune diseases. The new $230 million collaboration will harness the collective knowledge and resources...

2014-02-04 12:27:31

Lupus Foundation of America Joins a Five-Year Initiative to Bring Together Government, Academia, Industry and Nonprofit Health Organizations to Harness Capabilities and Resources WASHINGTON, Feb. 4, 2014 /PRNewswire-USNewswire/ -- The Lupus Foundation of America will partner with the Foundation for the National Institutes of Health (FNIH) to support a new five-year initiative that will accelerate the ability to develop new medicines for lupus and other diverse and complex diseases....


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related